Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 73

1.

MRI surveillance for hereditary breast-cancer risk.

Warner E, Causer PA.

Lancet. 2005 May 21-27;365(9473):1747-9. No abstract available.

PMID:
15910935
2.

Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS).

Leach MO, Boggis CR, Dixon AK, Easton DF, Eeles RA, Evans DG, Gilbert FJ, Griebsch I, Hoff RJ, Kessar P, Lakhani SR, Moss SM, Nerurkar A, Padhani AR, Pointon LJ, Thompson D, Warren RM; MARIBS study group.

Lancet. 2005 May 21-27;365(9473):1769-78. Erratum in: Lancet. 2005 May 28-Jun 3;365(9474):1848.

PMID:
15910949
3.

Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination.

Warner E, Plewes DB, Hill KA, Causer PA, Zubovits JT, Jong RA, Cutrara MR, DeBoer G, Yaffe MJ, Messner SJ, Meschino WS, Piron CA, Narod SA.

JAMA. 2004 Sep 15;292(11):1317-25.

PMID:
15367553
4.

Breast magnetic resonance image screening and ductal lavage in women at high genetic risk for breast carcinoma.

Hartman AR, Daniel BL, Kurian AW, Mills MA, Nowels KW, Dirbas FM, Kingham KE, Chun NM, Herfkens RJ, Ford JM, Plevritis SK.

Cancer. 2004 Feb 1;100(3):479-89.

5.

Effectiveness of screening with annual magnetic resonance imaging and mammography: results of the initial screen from the ontario high risk breast screening program.

Chiarelli AM, Prummel MV, Muradali D, Majpruz V, Horgan M, Carroll JC, Eisen A, Meschino WS, Shumak RS, Warner E, Rabeneck L.

J Clin Oncol. 2014 Jul 20;32(21):2224-30. doi: 10.1200/JCO.2013.52.8331. Epub 2014 Jun 16.

PMID:
24934793
6.

Mammographic, US, and MR imaging phenotypes of familial breast cancer.

Schrading S, Kuhl CK.

Radiology. 2008 Jan;246(1):58-70.

PMID:
18096529
7.

Re: Magnetic resonance imaging and mammography in women with a hereditary risk of breast cancer.

Goffin J, Chappuis PO, Wong N, Foulkes WD.

J Natl Cancer Inst. 2001 Nov 21;93(22):1754-5. No abstract available.

PMID:
11717339
8.

Improvement in DCIS detection rates by MRI over time in a high-risk breast screening study.

Warner E, Causer PA, Wong JW, Wright FC, Jong RA, Hill KA, Messner SJ, Yaffe MJ, Narod SA, Plewes DB.

Breast J. 2011 Jan-Feb;17(1):9-17. doi: 10.1111/j.1524-4741.2010.01018.x.

PMID:
21251121
9.

Survival of patients with BRCA1-associated breast cancer diagnosed in an MRI-based surveillance program.

Møller P, Stormorken A, Jonsrud C, Holmen MM, Hagen AI, Clark N, Vabø A, Sun P, Narod SA, Mæhle L.

Breast Cancer Res Treat. 2013 May;139(1):155-61. doi: 10.1007/s10549-013-2540-z. Epub 2013 Apr 25.

PMID:
23615785
10.

Triple-modality screening trial for familial breast cancer underlines the importance of magnetic resonance imaging and questions the role of mammography and ultrasound regardless of patient mutation status, age, and breast density.

Riedl CC, Luft N, Bernhart C, Weber M, Bernathova M, Tea MK, Rudas M, Singer CF, Helbich TH.

J Clin Oncol. 2015 Apr 1;33(10):1128-35. doi: 10.1200/JCO.2014.56.8626. Epub 2015 Feb 23.

11.

Differences between first and subsequent rounds of the MRISC breast cancer screening program for women with a familial or genetic predisposition.

Kriege M, Brekelmans CT, Boetes C, Muller SH, Zonderland HM, Obdeijn IM, Manoliu RA, Kok T, Rutgers EJ, de Koning HJ, Klijn JG; Dutch MRI Screening (MRISC) Study Group.

Cancer. 2006 Jun 1;106(11):2318-26.

12.

BRCA1-associated breast cancers present differently from BRCA2-associated and familial cases: long-term follow-up of the Dutch MRISC Screening Study.

Rijnsburger AJ, Obdeijn IM, Kaas R, Tilanus-Linthorst MM, Boetes C, Loo CE, Wasser MN, Bergers E, Kok T, Muller SH, Peterse H, Tollenaar RA, Hoogerbrugge N, Meijer S, Bartels CC, Seynaeve C, Hooning MJ, Kriege M, Schmitz PI, Oosterwijk JC, de Koning HJ, Rutgers EJ, Klijn JG.

J Clin Oncol. 2010 Dec 20;28(36):5265-73. doi: 10.1200/JCO.2009.27.2294. Epub 2010 Nov 15.

PMID:
21079137
13.

MRI screening in a clinic population with a family history of breast cancer.

Yu J, Park A, Morris E, Liberman L, Borgen PI, King TA.

Ann Surg Oncol. 2008 Feb;15(2):452-61. Epub 2007 Nov 17.

PMID:
18026801
14.

Breast MRI: opportunities and challenges.

Day D.

Minn Med. 2009 Dec;92(12):45-8.

PMID:
20092173
15.

Cost-effectiveness of screening women with familial risk for breast cancer with magnetic resonance imaging.

Saadatmand S, Tilanus-Linthorst MM, Rutgers EJ, Hoogerbrugge N, Oosterwijk JC, Tollenaar RA, Hooning M, Loo CE, Obdeijn IM, Heijnsdijk EA, de Koning HJ.

J Natl Cancer Inst. 2013 Sep 4;105(17):1314-21. doi: 10.1093/jnci/djt203. Epub 2013 Aug 12.

PMID:
23940285
16.

Long-term results of screening with magnetic resonance imaging in women with BRCA mutations.

Passaperuma K, Warner E, Causer PA, Hill KA, Messner S, Wong JW, Jong RA, Wright FC, Yaffe MJ, Ramsay EA, Balasingham S, Verity L, Eisen A, Curpen B, Shumak R, Plewes DB, Narod SA.

Br J Cancer. 2012 Jun 26;107(1):24-30. doi: 10.1038/bjc.2012.204. Epub 2012 May 15.

17.

Clinical practice. Management of an inherited predisposition to breast cancer.

Robson M, Offit K.

N Engl J Med. 2007 Jul 12;357(2):154-62. Review. No abstract available.

PMID:
17625127
18.

A systematic review of the effectiveness of magnetic resonance imaging (MRI) as an addition to mammography and ultrasound in screening young women at high risk of breast cancer.

Lord SJ, Lei W, Craft P, Cawson JN, Morris I, Walleser S, Griffiths A, Parker S, Houssami N.

Eur J Cancer. 2007 Sep;43(13):1905-17. Epub 2007 Aug 2. Review.

PMID:
17681781
19.

Differences in natural history between breast cancers in BRCA1 and BRCA2 mutation carriers and effects of MRI screening-MRISC, MARIBS, and Canadian studies combined.

Heijnsdijk EA, Warner E, Gilbert FJ, Tilanus-Linthorst MM, Evans G, Causer PA, Eeles RA, Kaas R, Draisma G, Ramsay EA, Warren RM, Hill KA, Hoogerbrugge N, Wasser MN, Bergers E, Oosterwijk JC, Hooning MJ, Rutgers EJ, Klijn JG, Plewes DB, Leach MO, de Koning HJ.

Cancer Epidemiol Biomarkers Prev. 2012 Sep;21(9):1458-68. doi: 10.1158/1055-9965.EPI-11-1196. Epub 2012 Jun 28.

20.

Loss of heterozygosity at BRCA2 in a ductal carcinoma in situ and three invasive breast carcinomas in a family with a germline BRCA2 mutation.

Thomassen M, Kruse TA, Olsen KE, Borg A, Gerdes AM.

Breast Cancer Res Treat. 2004 Oct;87(3):273-6.

PMID:
15528970

Supplemental Content

Support Center